Age
|
47
|
25
|
55
|
Sex
|
Male
|
Male
|
Male
|
Prior therapies (no.)
|
6
|
6
|
5
|
Stem cell source
|
Matched-related
|
Matched-related
|
Haploidentical and umbilical cord blood
|
Conditioning regimen
|
Reduced intensity
|
Reduced intensity
|
Reduced intensity
|
T cell depleted graft
|
Yes
|
Yes
|
Yes
|
Prior GVHD
|
No
|
Chronic GVHD of gut
|
Chronic oral GVHD
|
Days to relapse following AlloHSCT (no.)
|
181
|
2456
|
389
|
Localization and size of relapse
|
Diffuse bone and splenic involvement
|
Multifocal adenopathy in mediastinum, retroperitoneum and pelvis. Largest lymph node 2.3 × 1.5 cm in mediastinum
|
Multifocal adenopathy in neck, chest, abdomen and pelvis. Largest lymph node 4.2 × 1.8 cm in right axilla
|
Prior DLI
|
No
|
Yes
|
No
|
Immune-related adverse events
|
Grade 2 Keratoconjunctivitis
|
Grade 3 Inflammatory polyarthritis and grade 2 keratoconjunctivitis
|
Grade 1 Rash
|
Response to nivolumab
|
Partial response
|
Partial response
|
Partial response
|
Duration of response
|
6 Months+
|
10 Months+
|
14 Months+
|
Donor CD3+ chimerism before and after treatment
|
18 to 49%
|
Not available
|
Not available
|